Full-Time

Molecular Lab Supervisor

Confirmed live in the last 24 hours

Tempus

Tempus

1,001-5,000 employees

AI-driven healthcare data analysis platform

AI & Machine Learning
Biotechnology
Healthcare

Mid, Senior

Durham, NC, USA

Category
Genomics
Lab & Research
Biology Lab & Research
Biology & Biotech
Requirements
  • MS in the Biological sciences with at least three years of experience or BS in the biological sciences with at least five years of experience
  • Ability to maintain the confidentiality of patient related materials in compliance with HIPAA requirements
  • Excellent communication skills
  • Thrives in a fast-paced environment
  • Must have experience working in a molecular lab; prefer experience with next-generation sequencing
  • Ability to work with others to plan and carry out scientific programs
  • Self-driven and works well in an interdisciplinary team with minimal direction
  • Strong desire to build products that will save lives and change the course of cancer
Responsibilities
  • Provide daily oversight of a cutting-edge molecular workflow to provide high-quality next-generation sequencing data with rapid turnaround times, including tumor genomic, germline genomic, and transcriptomic sequencing
  • Establish and maintain appropriate QC and QA programs
  • Maintain CLIA and CAP compliance regarding equipment, reagents, and staff training
  • Complete quality review of all samples within the NGS workflow from extraction to sequencing
  • Balance turnaround time while optimizing costs of sequencing workflow
  • Schedule training and competency assessments for personnel
  • Mentor junior staff

Tempus focuses on enhancing patient outcomes through the use of data and artificial intelligence in healthcare. The company offers a platform that analyzes medical data to provide insights for physicians, helping them make better treatment decisions. This platform also aids pharmaceutical and biotech companies in drug development by identifying new targets and assessing treatment effectiveness. For patients, Tempus identifies personalized therapy options, particularly in cancer care, where their research has shown increased opportunities for tailored treatments. They have developed a pan-cancer organoid platform and a liquid biopsy assay for profiling circulating tumor DNA. Tempus generates revenue by charging healthcare providers and companies for access to their platform and insights, setting them apart from competitors by their focus on personalized medicine and extensive cancer research.

Company Stage

IPO

Total Funding

$894.9M

Headquarters

Chicago, Illinois

Founded

2015

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • Increased AI adoption in healthcare boosts Tempus' partnerships and collaborations.
  • Acquisition of Ambry Genetics expands Tempus' genetic testing capabilities.
  • Integration with Flatiron's OncoEMR enhances precision in cancer treatment plans.

What critics are saying

  • Competition from partners like Genialis may lead to conflicts of interest.
  • Ambry Genetics acquisition could pose financial risks if synergies aren't realized.
  • Technical challenges may arise in integration with Flatiron's OncoEMR platform.

What makes Tempus unique

  • Tempus uses AI to analyze clinical and molecular data for precision medicine.
  • Their platform aids in personalized treatment decisions for cancer patients.
  • Tempus collaborates with biotech firms to enhance drug development using real-world data.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Relocation Assistance

Company Equity

Performance Bonus